Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Versus Placebo as Adjuvant Therapy in High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma
NCT03833167Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Primary completion
- Jun 2024
- Countries
- 24
01
Overview
A Phase 3 trial of pembrolizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Merck & Co.. Started Apr 2019; status: terminated.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT03833167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833167.